Ignite Creation Date:
2024-05-06 @ 4:59 PM
Last Modification Date:
2024-10-26 @ 2:20 PM
Study NCT ID:
NCT05156788
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-08-15
First Post:
2021-09-30
Brief Title:
TislelizumabAnti PD-1 Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable Locally Advanced Biliary Tract Cancer
Sponsor:
Shanghai Zhongshan Hospital
Organization:
Shanghai Zhongshan Hospital
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-12-12
Start Date Type:
ACTUAL
Primary Completion Date:
2023-07-03
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-10-01
Completion Date Type:
ESTIMATED
First Submit Date:
2021-09-30
First Submit QC Date:
December 11 2021
Study First Post Date:
2021-12-14
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-08-14
Last Update Post Date:
2023-08-15
Last Update Post Date Type:
ACTUAL